3 High-Yielding Dividend Stocks That Just Raised Their Payouts

Lowe's raised its quarterly dividend 4% to $1.25, Medtronic lifted its payout by $0.01 to $0.72, and UnitedHealth increased its quarterly dividend 5% to $2.32. The three stocks now yield 2.4%, 3.5%, and 2.3%, respectively, while also trading at relatively modest forward P/E multiples of 16, 12, and 21. The article frames them as attractive dividend-growth names with defensive characteristics and above-average income.

Analysis

The common setup across these names is not just “yield plus value,” but a late-cycle cash-return trade hiding in plain sight. When growth slows and multiples compress, the market starts paying up for balance-sheet durability and payout consistency, which tends to favor companies with recurring demand and pricing power over pure cyclicals. In that sense, the real winner is the income sleeve of the market: investors rotating out of crowded mega-cap growth can find similar or better total-return characteristics with less duration risk.

Lowe’s looks most levered to a cyclical normalization over the next 6-12 months. The stock has already discounted softer DIY demand, so incremental upside likely comes from a stabilization in housing turnover and renovation spending rather than a strong housing rebound; that makes the setup asymmetric if rates drift lower. The second-order beneficiary is the broader home-improvement supply chain, but the bigger risk is that delayed maintenance demand keeps stretching longer than expected, which would cap any multiple re-rating.

Medtronic and UnitedHealth sit in the defensive growth bucket, but the market is likely underestimating how much capital efficiency improves when healthcare names can compound dividends while maintaining modest revenue acceleration. For UNH, the key is not the dividend itself but whether medical cost trends stay contained long enough for sentiment to rebuild over multiple quarters; if they do, the stock can rerate before earnings growth fully inflects. The contrarian read is that these are not “bond proxies” in a falling-rate regime — they are operational turnarounds with lower volatility, and that usually deserves a premium once the market stops penalizing them for near-term noise.

Key Decisions for Investors

• Long LOW on a 3-6 month horizon: buy into weakness near current levels for a mean-reversion trade back toward a mid-teens multiple; target 15-20% upside plus ~2.4% yield, with downside limited if housing data merely stops worsening.
• Pair trade: long UNH / short a higher-beta managed-care basket over 6-12 months. If medical cost ratios keep normalizing, UNH should outperform on both multiple recovery and dividend growth while the short leg remains vulnerable to margin disappointment.
• Add MDT as a defensive income compounder, but size smaller than UNH: use it as a 12-18 month hold where the thesis is cash return plus low earnings volatility; expect lower near-term torque, but better downside protection if the market turns risk-off.
• For income-focused portfolios, rotate part of large-cap growth exposure into LOW/MDT/UNH as a volatility reduction trade. The expected reward is modest absolute alpha, but the risk-adjusted return should improve if rates stay range-bound and recession odds remain contained.
• Avoid chasing after any short-term bounce in LOW until housing-related data stabilizes. If same-store demand or housing turnover continues to weaken for another quarter, the stock can stay cheap longer than expected despite the dividend support.